The available delivery strategies can be broken down into two major categories: in vivo gene editing (from the Latin for “within the living,” as mentioned earlier) and ex vivo gene editing (from the Latin for “out of the living”). In the former approach, CRISPR is sent directly into the body of the patient to do its work onsite; in the latter, the patient’s cells are edited outside of the body and then placed back into the patient.
